CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Mylan Pharma Acquisition Ltd. v. Fresenius Kabi USA, LLC

1:15-cv-06700

Overview

Case Number 1:15-cv-06700
Filing Date 2015-07-30
Status Terminated
Termination Date 2017-02-01
Court District Court, N.D. Illinois (ilnd)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Fresenius Kabi USA, LLC Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Plaintiff

Mylan Pharma Acquisition Ltd. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Court & Judges

Court

District Court, N.D. Illinois (ilnd)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 2 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (2): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US5866591
Stable formulations of remifentanil
Filed: 1997-09-10
Issued: 1999-02-02
Expired (Term Ended)
Expires: 2017-09-10

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

78

Dispositive

15

Granted

5

Denied

1

Pending / Review

72

Motions by Category

Procedural / Extension Motion 25 Motion to Compel Discovery 26 Claim Construction / Markman Filing 12 Motion for Summary Judgment (Rule 56) 11 Motion for Summary Judgment (Infringement) 1 Motion for Summary Judgment (Invalidity) 3

Key Dispositive Motions & Rulings

Motion for Summary Judgment (Rule 56) Pending / Under Review
MINUTE entry before the Honorable Rebecca R. Pallmeyer: Joint Stipulation to extend summary judgment deadlines 224 granted. Reply Brief in support of Fresenius ...
Entry #225 • 2017-01-20 Document →
Motion for Summary Judgment (Rule 56) Pending / Under Review
MINUTE entry before the Honorable Rebecca R. Pallmeyer: Motion to compel 219 is granted in part and denied in part. Fresenius Kabi USA, LLC will have leave to t...
Entry #221 • 2017-01-06 Document →
Motion for Summary Judgment (Invalidity) Pending / Under Review
SEALED RESPONSE by Mylan Institutional LLC, Mylan Pharma Acquisition Ltd., Mylan Teoranta to statement in support 142 of Motion for Summary Judgment of Invalidi...
Entry #216 • 2016-12-16 Document →
Motion for Summary Judgment (Invalidity) Pending / Under Review
MOTION by Plaintiffs Mylan Institutional LLC, Mylan Pharma Acquisition Ltd., Mylan Teoranta for leave to file excess pages INSTANTER IN RESPONSE TO FRESENIUS MO...
Entry #211 • 2016-12-15 Document →
Motion for Summary Judgment (Invalidity) Pending / Under Review
REPLY by Plaintiffs Mylan Institutional LLC, Mylan Pharma Acquisition Ltd., Mylan Teoranta to statement in support 142 of Motion for Summary Judgment of Invalid...
Entry #214 • 2016-12-15 Document →
Motion for Summary Judgment (Rule 56) Pending / Under Review
MINUTE entry before the Honorable Rebecca R. Pallmeyer: Defendants ask the court to reconsider its decision to extend, by 30 days, the briefing schedule on Defe...
Entry #196 • 2016-10-31 Document →

Docket Entries

(230 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed by Mylan Pharma Acquisition Ltd., Mylan Institutional LLC, Mylan Teoranta; Filing fee $ 400, receipt number 0752-10924765. (Attachments: # 1 Exhibit A - United States Patent No. 5,866,591)(Mandell, Steven) (Entered: 07/30/2015)

Entry #1 • 2015-07-30
1

CIVIL Cover Sheet (Mandell, Steven) (Entered: 07/30/2015)

Entry #2 • 2015-07-30
1

ATTORNEY Appearance for Plaintiffs Mylan Institutional LLC, Mylan Pharma Acquisition Ltd., Mylan Teoranta by Steven P. Mandell (Mandell, Steven) (Entered: 07/30/2015)

Entry #3 • 2015-07-30
1

ATTORNEY Appearance for Plaintiffs Mylan Institutional LLC, Mylan Pharma Acquisition Ltd., Mylan Teoranta by Rebecca Ann Edwards (Edwards, Rebecca) (Entered: 07/30/2015)

Entry #4 • 2015-07-30
1

Notice of Claims Involving Patents by Mylan Institutional LLC, Mylan Pharma Acquisition Ltd., Mylan Teoranta (Edwards, Rebecca) (Entered: 07/30/2015)

Entry #5 • 2015-07-30
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc